Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polyvalent pneumococcal polysaccharide vaccines.

M R Hilleman, A A McLean, P P Vella

    Bulletin of the World Health Organization
    |January 1, 1978
    PubMed
    Summary

    A new 14-valent pneumococcal vaccine shows high antibody production and significantly reduces pneumococcal pneumonia rates. However, younger children may have varied responses, and booster efficacy in adults is unknown.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The enhancement and properties of the complement-fixing antigens of lymphogranuloma venereum.

    Federation proceedings·2010
    Same author

    Studies on lymphogranuloma venereum complement-fixing antigens the solubility in ether of an active fraction.

    Journal of immunology (Baltimore, Md. : 1950)·2010
    Same author

    Studies on lymphogranuloma venereum complement-fixing antigens; enhancement by phenol or boiling.

    Journal of immunology (Baltimore, Md. : 1950)·2010
    Same author

    Studies on lymphogranuloma venereum complement-fixing antigens; fractionation with organic solvents of antigens of the psittacosis lymphogranuloma venereum group.

    Journal of bacteriology·2010
    Same author

    On use of urea- and phenol-treated skin test antigens for diagnosis of lymphogranuloma venereum.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
    Same author

    The case of H. R., a discussion of certain manifestations of the basic sexual conflicts.

    MD (Chicago, Ill.)·2010

    Area of Science:

    • Immunology
    • Vaccinology
    • Pediatrics

    Background:

    • Pneumococcal pneumonia remains a significant public health concern.
    • Development of effective vaccines is crucial for disease prevention.

    Purpose of the Study:

    • To evaluate the efficacy and immunogenicity of a newly licensed 14-valent pneumococcal vaccine.
    • To assess vaccine response in different age groups and identify potential limitations.

    Main Methods:

    • Clinical trials involving human subjects.
    • Measurement of antibody production post-vaccination.
    • Assessment of reduction in pneumococcal pneumonia incidence.

    Main Results:

    • Satisfactory antibody production in 92% of individuals.

    Related Experiment Videos

  • Significant reduction (76-92%) in vaccine-type pneumococcal pneumonia.
  • Variable response in children under 2 years old.
  • Unknown duration of protection and limited booster response in adults.

    • Conclusions:

    • The 14-valent pneumococcal vaccine is effective in reducing pneumonia caused by vaccine serotypes.
    • Further research is needed to optimize vaccination strategies for young children and assess long-term immunity in adults.